24/03/20 -"Our higher target price reflects a significant increase in our intrinsic valuation, driven by our belief that the business is now on a firm footing to focus on topline growth/margin expansion, ..."
Pages
65
Language
English
Published on
24/03/20
You may also be interested by these reports :
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...